The world of medicine might be on the brink of a major change. OpenAI, the company that created ChatGPT, is now talking with the FDA about using artificial intelligence to speed up how new medicines get approved. 

These discussions could transform a process that currently takes over 10 years into something much faster. Imagine new treatments for diseases reaching patients months earlier because AI helped review the mountains of data that normally slow things down.

While this technology brings hope, it also raises important questions about safety and reliability. 

In this article, we'll explore what's happening between OpenAI and the FDA, why drug approvals take so long now, how AI might change things, what concerns experts have, and what other companies are doing in this exciting space.

Let's get into it.